Literature DB >> 12369855

Design and discovery of small molecules targeting raf-1 kinase.

Timothy B Lowinger1, Bernd Riedl, Jacques Dumas, Roger A Smith.   

Abstract

Raf kinase, an enzyme which acts downstream in the Ras signaling pathway, is involved in cancerous cell proliferation. Thus, small molecule inhibitors of Raf kinase activity may be important agents for the treatment of cancer. A novel class of Raf-1 inhibitors was discovered, using a combination of medicinal and combinatorial chemistry approaches. This effort culminated in the identification of the clinical candidate BAY 43-9006, currently undergoing Phase I clinical trials. The present review summarizes the medicinal chemistry development of ureas as highly potent inhibitors of Raf-1 kinase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12369855     DOI: 10.2174/1381612023393125

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  31 in total

Review 1.  The discovery and development of sorafenib for the treatment of thyroid cancer.

Authors:  Peter T White; Mark S Cohen
Journal:  Expert Opin Drug Discov       Date:  2015-02-08       Impact factor: 6.098

Review 2.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 3.  Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.

Authors:  Michael J Schnieders; Tamer S Kaoud; Chunli Yan; Kevin N Dalby; Pengyu Ren
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states.

Authors:  Irina Kufareva; Ruben Abagyan
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

5.  A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.

Authors:  Douglas S Auld; Ya-Qin Zhang; Noel T Southall; Ganesha Rai; Marc Landsman; Jennifer MacLure; Daniel Langevin; Craig J Thomas; Christopher P Austin; James Inglese
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 6.  Ten things you should know about protein kinases: IUPHAR Review 14.

Authors:  Doriano Fabbro; Sandra W Cowan-Jacob; Henrik Moebitz
Journal:  Br J Pharmacol       Date:  2015-03-24       Impact factor: 8.739

7.  Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.

Authors:  Angela Gauthier; Mitchell Ho
Journal:  Hepatol Res       Date:  2012-11-12       Impact factor: 4.288

8.  Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.

Authors:  Arati Sharma; Melissa A Tran; Shile Liang; Arun K Sharma; Shantu Amin; Charles D Smith; Cheng Dong; Gavin P Robertson
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

9.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

10.  2-Methyl-carbamoyl-4-{4-[3-(trifluoro-meth-yl)benzamido]phen-oxy}pyridinium 4-methyl-benzene-sulfonate monohydrate.

Authors:  Zhao Wang; Na-Na Meng; Ting-Ting Huang; Yong-Kui Zhang; Luo-Ting Yu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.